Zacks Research Has Negative Estimate for EW Q2 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Zacks Research reduced their Q2 2025 earnings per share estimates for Edwards Lifesciences in a report released on Tuesday, March 4th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $0.60 for the quarter, down from their previous estimate of $0.62. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q3 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.62 EPS, Q1 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.69 EPS and FY2027 earnings at $3.07 EPS.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%.

A number of other research analysts have also recently weighed in on the company. Evercore ISI lowered their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Piper Sandler lifted their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Trading Down 1.5 %

Shares of NYSE:EW opened at $71.79 on Wednesday. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market capitalization of $42.34 billion, a price-to-earnings ratio of 10.30, a PEG ratio of 4.82 and a beta of 1.10. The stock’s 50-day simple moving average is $72.36 and its two-hundred day simple moving average is $70.36.

Insiders Place Their Bets

In other news, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock valued at $2,799,104 in the last quarter. 1.29% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the stock. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $26,000. Vega Investment Solutions purchased a new position in Edwards Lifesciences during the 4th quarter valued at $27,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at $29,000. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences during the 3rd quarter valued at $30,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences during the 4th quarter valued at $30,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.